The FDA’s Pharmacy Compounding Advisory Committee (PCAC) recently recommended that six of seven peptides under review be added to the 503A Bulks List, a potentially significant development for compounding pharmacies, prescribers, and businesses operating in the rapidly evolving peptide industry.
In an article published by Dispense Times, Frier Levitt attorneys Guilherme Faviero, Jesse Dresser, and Edgar J. Asebey examine the July 2026 PCAC votes, the legal significance of the recommendations, and what businesses should be watching as the FDA determines its next steps.
What Did PCAC Recommend for BPC-157 and Other Peptides?
During its July 23–24, 2026 meeting, PCAC considered seven peptide bulk drug substances for potential inclusion on the 503A Bulks List. The committee recommended inclusion of:
- BPC-157
- KPV
- TB-500
- MOTS-c
- Epitalon
- Semax
The committee recommended against inclusion of emideltide, also known as DSIP. The favorable recommendations were particularly notable because FDA scientific staff had recommended against adding all seven substances.
Does the PCAC Vote Mean These Peptides Can Now Be Compounded?
No. The PCAC recommendations are advisory and do not themselves change the legal status of the peptides. The FDA must take additional action, including formal rulemaking, before any of the recommended substances can be added to the 503A Bulks List.
For compounding pharmacies, prescribers, peptide businesses, and other industry participants, that distinction is critical. The July vote represents an important regulatory development, but it should not be interpreted as FDA approval or an immediate authorization to compound these substances under Section 503A.
What Does the PCAC Peptide Decision Mean for the Industry?
In their Dispense Times article, Faviero, Dresser, and Asebey analyze what comes next for the six recommended peptides and the broader peptide market, including the potential FDA rulemaking process, continued enforcement considerations, the research-use-only (RUO) market, and compliance risks for businesses operating while the regulatory framework remains unsettled.
For additional updates on peptide regulation, FDA developments, enforcement, compounding, and emerging business models, visit Frier Levitt’s Peptides: Legal and Regulatory Resource Center.
Frequently Asked Questions About the 2026 PCAC Peptide Recommendations
Which peptides did PCAC recommend for the 503A Bulks List?
PCAC recommended BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. It recommended against emideltide (DSIP).
Can 503A pharmacies compound BPC-157 now because of the PCAC vote?
No. A favorable PCAC recommendation does not itself place BPC-157 or the other peptides on the 503A Bulks List. Additional FDA action is required.
Is a PCAC recommendation the same as FDA approval?
No. PCAC serves an advisory role. Its recommendation is not FDA approval and does not independently change federal law or the regulatory status of a substance.
What should peptide and compounding businesses do next?
Businesses should continue monitoring FDA rulemaking, guidance, enforcement activity, and related federal and state regulatory developments rather than treating the PCAC recommendations as an immediate change in law.
Senior Associate
